Identify Patients

In asymptomatic or minimally symptomatic mCRPC patients, treat them early with PROVENGE Immunotherapy

6 month duration

Treat early

  • To stimulate your mCRPC patients’ immune systems while they have a lower tumor burden1

NCCN category 1 recommendation

  • NCCN guidelines maintain PROVENGE as a first-line treatment and a prominent category 1 designation2
  • NCCN guidelines support the use of PROVENGE before enzalutamide, abiraterone, chemotherapy, and other treatments in asymptomatic or minimally symptomatic mCRPC patients2

PROVENGE does not preclude the use of subsequent therapies2,3

*Radiographic evidence of disease progression or rising prostate-specific antigen (PSA).
ADT=androgen deprivation therapy; mCRPC=metastatic castrate-resistant prostate cancer; NCCN=National Comprehensive Cancer Network.

Most CRPC patients fit in the PROVENGE window at the time of metastatic diagnosis

6 month duration

Treat early — make sure your patients take advantage of the PROVENGE window

Keep in mind that if your patient:

Candidate for Provenge

He may be a candidate for PROVENGE3

*Radiographic evidence of disease progression or rising PSA.

Learn about Mike's Experience with PROVENGE

Dendreon uses cookies to analyze traffic, enhance your experience, and provide you with tailored content. By continuing to use this site, you agree with our use of cookies and our Privacy Policy. For more information or to opt-out of sale, visit our Privacy Policy.